Kelun Pharmaceutical gets nod for 3 bn yuan medium-term notes

Sichuan Kelun Pharmaceutical Co., Ltd. announced that its application for the registration of non-financial enterprise debt financing instruments, specifically medium-term notes, has been approved. The company received a "Notice of Acceptance of Registration" from the National Association of Financial Market Institutional Investors on September 16, 2025.

The board of directors initially approved the issuance on April 22, 2025, followed by approval from the 2024 annual general meeting of shareholders on May 19, 2025. The registered amount for the medium-term notes is 3 bn yuan, with a validity period of two years. CITIC Bank Co., Ltd. will serve as the lead underwriter.

Sichuan Kelun Pharmaceutical stated its intention to issue the notes in phases, based on its funding requirements and prevailing market conditions. The company is committed to timely disclosure of information regarding these issuances.